Literature DB >> 29698959

Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination.

Benjamin Koch1, Patricia Schult-Dietrich2, Stefan Büttner1, Bijan Dilmaghani1, Dario Lohmann1, Patrick C Baer1, Ursula Dietrich2, Helmut Geiger1.   

Abstract

BACKGROUND/AIMS: Middle East respiratory syndrome coronavirus (MERS-CoV) and Marburg virus (MARV) are among the World Health Organization's top 8 emerging pathogens. Both zoonoses share nonspecific early symptoms, a high lethality rate, and a reduced number of specific treatment options. Therefore, we evaluated extracorporeal virus and glycoprotein (GP) elimination by lectin affinity plasmapheresis (LAP).
METHODS: For both MERS-CoV (pseudovirus) as well as MARV (GPs), 4 LAP devices (Mini Hemopurifiers, Aethlon Medical, San Diego, CA, USA) and 4 negative controls were tested. Samples were collected every 30 min and analyzed for reduction in virus infectivity by a flow cytometry-based infectivity assay (MERS-CoV) and in soluble GP content (MARV) by an immunoassay.
RESULTS: The experiments show a time-dependent clearance of MERS-CoV of up to 80% within 3 h (pseudovirus). Up to 70% of MARV-soluble GPs were eliminated at the same time. Substantial saturation of the binding resins was detected within the first treatment hour.
CONCLUSION: MERS-CoV (pseudovirus) and MARV soluble GPs are eliminated by LAP in vitro. Considering the high lethality and missing established treatment options, LAP should be evaluated in vivo. Especially early initiation, continuous therapy, and timed cartridge exchanges could be of importance. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Extracorporeal purification; Lectin affinity plasmapheresis; Marburg virus; Middle East respiratory syndrome coronavirus

Mesh:

Substances:

Year:  2018        PMID: 29698959      PMCID: PMC6008873          DOI: 10.1159/000487224

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  37 in total

1.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

2.  Extracorporeal virus elimination for the treatment of severe Ebola virus disease--first experience with lectin affinity plasmapheresis.

Authors:  Stefan Büttner; Benjamin Koch; Olga Dolnik; Markus Eickmann; Tilo Freiwald; Sarah Rudolf; Jürgen Engel; Stephan Becker; Claudio Ronco; Helmut Geiger
Journal:  Blood Purif       Date:  2015-02-11       Impact factor: 2.614

3.  [On the etiology of an unknown human infection originating from monkeys].

Authors:  R Siegert; H L Shu; W Slenczka; D Peters; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1967-12-22       Impact factor: 0.628

4.  Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study.

Authors:  Yaseen M Arabi; Awad Al-Omari; Yasser Mandourah; Fahad Al-Hameed; Anees A Sindi; Basem Alraddadi; Sarah Shalhoub; Abdullah Almotairi; Kasim Al Khatib; Ahmed Abdulmomen; Ismael Qushmaq; Ahmed Mady; Othman Solaiman; Abdulsalam M Al-Aithan; Rajaa Al-Raddadi; Ahmed Ragab; Ghaleb A Al Mekhlafi; Abdulrahman Al Harthy; Ayman Kharaba; Mashael Al Ahmadi; Musharaf Sadat; Hanan Al Mutairi; Eman Al Qasim; Jesna Jose; Maliha Nasim; Abdulaziz Al-Dawood; Laura Merson; Robert Fowler; Frederick G Hayden; Hanan H Balkhy
Journal:  Crit Care Med       Date:  2017-10       Impact factor: 7.598

5.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

8.  The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.

Authors:  Patrick Younan; Palaniappan Ramanathan; Jessica Graber; Fabian Gusovsky; Alexander Bukreyev
Journal:  MBio       Date:  2017-04-25       Impact factor: 7.867

9.  Transmission potential and design of adequate control measures for Marburg hemorrhagic fever.

Authors:  Marco Ajelli; Stefano Merler
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.

Authors:  Yang Yang; Fei Ye; Na Zhu; Wenling Wang; Yao Deng; Zhengdong Zhao; Wenjie Tan
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

View more
  13 in total

Review 1.  Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19.

Authors:  Ramtin Pourahmad; Bobak Moazzami; Nima Rezaei
Journal:  SN Compr Clin Med       Date:  2020-07-31

Review 2.  Renal replacement therapy for critically ill patients with COVID-19-associated acute kidney injury: A review of current knowledge.

Authors:  Rasha Samir Shemies; Eman Nagy; Dalia Younis; Hussein Sheashaa
Journal:  Ther Apher Dial       Date:  2021-08-27       Impact factor: 2.195

Review 3.  COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup.

Authors:  Mitra K Nadim; Lui G Forni; Ravindra L Mehta; Michael J Connor; Kathleen D Liu; Marlies Ostermann; Thomas Rimmelé; Alexander Zarbock; Samira Bell; Azra Bihorac; Vincenzo Cantaluppi; Eric Hoste; Faeq Husain-Syed; Michael J Germain; Stuart L Goldstein; Shruti Gupta; Michael Joannidis; Kianoush Kashani; Jay L Koyner; Matthieu Legrand; Nuttha Lumlertgul; Sumit Mohan; Neesh Pannu; Zhiyong Peng; Xose L Perez-Fernandez; Peter Pickkers; John Prowle; Thiago Reis; Nattachai Srisawat; Ashita Tolwani; Anitha Vijayan; Gianluca Villa; Li Yang; Claudio Ronco; John A Kellum
Journal:  Nat Rev Nephrol       Date:  2020-10-15       Impact factor: 28.314

Review 4.  Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.

Authors:  Ying Li; Shanglong Liu; Shuchao Zhang; Qiang Ju; Shaoqiang Zhang; Yuanming Yang; Haiyan Wang
Journal:  Transfus Apher Sci       Date:  2020-06-03       Impact factor: 1.764

5.  Should the Therapeutic Apheresis Method Be Added to Treatment in the COVID-19 Outbreak?

Authors:  Mustafa Şahin; Abdülkerim Yıldız
Journal:  Blood Purif       Date:  2021-03-15       Impact factor: 2.614

Review 6.  Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators.

Authors:  Monica D Reece; Ruby R Taylor; Colin Song; Christina Gavegnano
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

7.  Effect of adult COVID-19 surge on the provision of kidney replacement therapy in children.

Authors:  Akash Deep
Journal:  Pediatr Nephrol       Date:  2020-08-05       Impact factor: 3.714

8.  Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum.

Authors:  Claudio Ronco; Thiago Reis; Silvia De Rosa
Journal:  Blood Purif       Date:  2020-03-13       Impact factor: 2.614

9.  Severe COVID-19: A multifaceted viral vasculopathy syndrome.

Authors:  Cynthia M Magro; Justin Mulvey; Jeffrey Kubiak; Sheridan Mikhail; David Suster; A Neil Crowson; Jeffrey Laurence; Gerard Nuovo
Journal:  Ann Diagn Pathol       Date:  2020-10-13       Impact factor: 2.090

Review 10.  Man-Specific Lectins from Plants, Fungi, Algae and Cyanobacteria, as Potential Blockers for SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) Coronaviruses: Biomedical Perspectives.

Authors:  Annick Barre; Els J M Van Damme; Mathias Simplicien; Sophie Le Poder; Bernard Klonjkowski; Hervé Benoist; David Peyrade; Pierre Rougé
Journal:  Cells       Date:  2021-06-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.